Skip to content

Characteristics and Treatment Outcomes of Dupilumab in Super-Responders versus Treatment-Resistant Patients with Atopic Dermatitis in China: A Single-Center Retrospective Study

Characteristics and Treatment Outcomes of Dupilumab in Super-Responders versus Treatment-Resistant Patients with Atopic Dermatitis in China: A Single-Center Retrospective Study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600116110
Enrollment
Unknown
Registered
2026-01-05
Start date
2025-06-10
Completion date
Unknown
Last updated
2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atopic Dermatitis

Interventions

super responders (SRs):None
Mediocre responders (MRs):None
treatment-resistant patients (TRPs):None

Sponsors

The First Affiliated Hospital of Army Medical University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1.Clinically diagnosed according to the Hanifin & Rajka criteria; 2.Baseline SCORing Atopic Dermatitis (SCORAD) index >= 25; 3.Follow-up duration >= 52 weeks; 4.Complete dataset available, particularly all grouping-related scores including SCORAD, Eczema Area and Severity Index (EASI), and Peak Pruritus Numerical Rating Scale (pp-NRS).

Exclusion criteria

Exclusion criteria: 1.Presence of active skin diseases other than AD, or comorbidities affecting blood cell counts (e.g., infections, recent surgery, malignancies); 2.Secondary infections, ulcerations, or other skin lesions at affected sites that may interfere with treatment efficacy evaluation; 3.Incomplete clinical data (e.g., missing SCORAD or EASI scores).

Design outcomes

Primary

MeasureTime frame
Scoring atopic dermatitis index;

Secondary

MeasureTime frame
Eczema Area and Severity Index;Peak Pruritus Numerical Rating Scale score;

Countries

China

Contacts

Public ContactZhiqiang Song

The First Affiliated Hospital of Army Medical University

drsongzq@hotmail.com+86 23 6876 6347

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026